More News! 8 Feb 2017 The FDA lays down Laws of Interchangeability: New Era for Biosimilars? The new guidelines from the FDA on interchangeability may bring the US biosimilar market up to speed and a new opportunity for European companies. Though the US has long been seen as the most promising market for biosimilars due to the size of the market and high drug prices driving an interest in more affordable options, […] February 8, 2017 - 4 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 6 Dec 2016 Sanofi Jumps into the Biosimilars Market aiming for Asia Sanofi is joining the biosimilars trend to challenge Roche’s best-selling biological with a partnership that aims to take over the Chinese cancer market. Sanofi is going after the €6.8B ($7.3B) that Roche’s Rituxan/MabThera (rituximab), the second top-selling biological, made last year in revenues. The French pharma has signed a deal worth up to €219M ($236M) […] December 6, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 17 Nov 2016 Boehringer’s Biosimilar could take a Chunk out of the Cancer Market Boehringer Ingelheim is getting ready to launch a biosimilar for Roche’s cancer blockbuster Avastin as soon as the patent expires. Can it overcome the fierce competition in a market expected to grow to 50% of the drug market by 2020? Boehringer Ingelheim just announced results from a Phase I trial showing that its biosimilar candidate […] November 17, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 17 Nov 2016 What’s in the Cards for a Biosimilar after it Launches As legal frameworks and regulatory pathways for biosimilars are in evolving all around the world, how will they affect the future of biosimilars? A biosimilar is a biological medicine that is similar to another already authorized for use, and they enter the market after the end of the patent of a biological drug. Biosimilars are […] November 17, 2016 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 31 Oct 2016 UPDATE: FDA rejects Sanofi’s promising Rheumatoid Arthritis Drug Sanofi and Regeneron (NY, US) have ruled their phase III clinical trial immunotherapy Sarilumab a huge success. Now awaiting US FDA and EMA approval, the results from the latest study were presented at the American College of Rheumatology (ACR) annual meeting in San Francisco. Should Sarilumab be approved, this immunotherapy will be used to treat […] October 31, 2016 - 3 minutesmins - By Dani Bancroft Share WhatsApp Twitter Linkedin Email
News and Trends 27 Oct 2016 Boehringer enters the Biosimilar War against Blockbuster Humira Boehringer Ingelheim just announced positive Phase III results for its Humira biosimilar. The company is joining many others in the fights to take a bite of the huge market that will be open for access when patents expire later this year. AbbVie’s Humira (adalimumab) is the best selling biological, with a jaw-dropping €13B ($14B) in […] October 27, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 26 Oct 2016 Biosimilars are all the rage, but how do they compare to Generics? Biosimilars could be the future of the pharmaceutical industry, as the market could grow 10-fold in the next 5 years. But how do they differ from generic drugs? During the past decade, Europe saw the emergence of a new type of drug: biosimilars. The concept of a “similar biological medicinal product” was adopted in EU […] October 26, 2016 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email